The Effect of Farnesoid X Receptor Agonist Tropifexor on Liver Damage in Rats with Experimental Obstructive Jaundice

Overview

Journal Acta Cir Bras

Specialty General Surgery

Date 2021 Nov 24

PMID 34818403

Citations 1

Authors

Huseyin Kilavuz

Umit Turan

Atilla Yoldas

Fatma Inanc Tolun

Burak Tanriverdi

Asli Yaylali

Abit Yaman

Mehmet Kemal Yener

Oktay Irkorucu

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate experimentally the effects of Tropifexor, a farnesoid X receptor agonist, on liver injury in rats with obstructive jaundice.

Methods: Forty healthy Wistar albino female rats were divided randomly in selected groups. These groups were the sham group, control group, vehicle solution group, Ursodeoxycholic acid group and Tropifexor group. Experimental obstructive jaundice was created in all groups, except the sham one. In the blood samples obtained, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin and direct bilirubin levels were established and recorded. Additionally, liver malondialdehyde, myeloperoxidase and catalase enzyme activity in the tissue samples were studied. Histopathological analysis was also performed.

Results: No statistical difference was found between the control group and the Tropifexor group when AST, ALT and ALP values were compared. However, it was found that the Tropifexor group had statistically significant decreases in the values of GGT, total bilirubin and direct bilirubin (p < 0.05). Additionally, Tropifexor decreased the median values of malondialdehyde and myeloperoxidase, but this difference was not statistically significant compared to the control group. Finally, the Tropifexor group was statistically significant in recurring histopathological liver damage indicators (p < 0.05).

Conclusions: Tropifexor reduced liver damage due to obstructive jaundice.

Citing Articles

Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.

Kasztelan-Szczerbinska B, Rycyk-Bojarzynska A, Szczerbinska A, Cichoz-Lach H Nutrients. 2023; 15(3).

PMID: 36771465 PMC: 9921714. DOI: 10.3390/nu15030760.

References

Livero F, Stolf A, Dreifuss A, Bastos-Pereira A, Chicorski R, de Oliveira L . The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol Interact. 2014; 217:19-27. DOI: 10.1016/j.cbi.2014.03.014. View

Turk O, Badak B, Ates E, Dundar E, Sutken E . The role of growth factors on hepatic damage in rats with obstructive jaundice. Springerplus. 2016; 5(1):1274. PMC: 4975730. DOI: 10.1186/s40064-016-2919-5. View

Wang L, Yu W . Obstructive jaundice and perioperative management. Acta Anaesthesiol Taiwan. 2014; 52(1):22-9. DOI: 10.1016/j.aat.2014.03.002. View

Zhang S, Wang J, Liu Q, Harnish D . Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009; 51(2):380-8. DOI: 10.1016/j.jhep.2009.03.025. View

Xie Y, Wang H, Cheng X, Wu Y, Cao L, Wu M . Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming. Sci Rep. 2016; 6:18751. PMC: 4700422. DOI: 10.1038/srep18751. View

Beuers U, Trauner M, Jansen P, Poupon R . New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015; 62(1 Suppl):S25-37. DOI: 10.1016/j.jhep.2015.02.023. View

Suzuki S, Rodriguez F, Cejalvo D . Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation. 1993; 55(6):1265-72. DOI: 10.1097/00007890-199306000-00011. View

Montilla P, Cruz A, Padillo F, Tunez I, Gascon F, Munoz M . Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J Pineal Res. 2001; 31(2):138-44. DOI: 10.1034/j.1600-079x.2001.310207.x. View

Chiang J . Bile acids: regulation of synthesis. J Lipid Res. 2009; 50(10):1955-66. PMC: 2739756. DOI: 10.1194/jlr.R900010-JLR200. View

10.

Ogetman Z, Dirlik M, Caglikulekci M, Canbaz H, Karabacak T, Yaylak F . The effect of aminoguanidine on blood and tissue lipid peroxidation in jaundiced rats with endotoxemia induced with LPS. J Invest Surg. 2006; 19(1):19-30. DOI: 10.1080/08941930500444396. View

11.

Tully D, Rucker P, Chianelli D, Williams J, Vidal A, Alper P . Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). J Med Chem. 2017; 60(24):9960-9973. DOI: 10.1021/acs.jmedchem.7b00907. View

12.

Hernandez E, Zheng L, Kim Y, Fang B, Liu B, Valdez R . Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. Hepatol Commun. 2019; 3(8):1085-1097. PMC: 6672390. DOI: 10.1002/hep4.1368. View

13.

Nevens F, Andreone P, Mazzella G, Strasser S, Bowlus C, Invernizzi P . A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. 2016; 375(7):631-43. DOI: 10.1056/NEJMoa1509840. View

14.

Hu Y, Liu X, Zhan W . Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. Drug Des Devel Ther. 2018; 12:2213-2221. PMC: 6052932. DOI: 10.2147/DDDT.S170518. View

15.

Luo W, Zhou X, Wang Q, Shao Y, Li Z, Zhao D . The application of Compont gel in chronic obstructive jaundice rats model. Acta Cir Bras. 2019; 34(5):e201900504. PMC: 6583931. DOI: 10.1590/s0102-865020190050000004. View

16.

Su C, Peng F, Lui W . Factors affecting morbidity and mortality in biliary tract surgery. World J Surg. 1992; 16(3):536-40. DOI: 10.1007/BF02104465. View

17.

Alturfan A, Aytac E, Emekli-Alturfan E, Yarat A, Saribeyoglu K, Pekmezci S . Serum total sialic acid as a novel complementary candidate marker of hepatic damage in obstructive jaundice. Ann Clin Lab Sci. 2014; 44(1):56-61. View

18.

Liu Y, Binz J, Numerick M, Dennis S, Luo G, Desai B . Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003; 112(11):1678-87. PMC: 281645. DOI: 10.1172/JCI18945. View

19.

Tsuji K, Kubota Y, Yamamoto S, Yanagitani K, Amoh Y, Takaoka M . Increased neutrophil chemotaxis in obstructive jaundice: an in vitro experiment in rats. J Gastroenterol Hepatol. 1999; 14(5):457-63. DOI: 10.1046/j.1440-1746.1999.01880.x. View

20.

Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman M, Landis C . The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019; 70(3):788-801. PMC: 6767458. DOI: 10.1002/hep.30509. View